ICLR vs. INCY: ICON vs. Incyte Stock Comparison

Company Profile

ICON (ICLR) and Incyte (INCY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while INCY is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Incyte (INCY) at 7.84% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for INCY.

For every dollar of sales, both ICON (ICLR) at 5.26% and Incyte (INCY) at 6.71% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Incyte (INCY) at 33.72% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both ICON (ICLR) at 0.76% and Incyte (INCY) at 21.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) at 4,173.33% delivers above-range EPS growth, while ICON (ICLR) at -71.56% falls into the bottom quartile — a wide split in earnings momentum.

Growth Metrics

Financial Strength

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while ICON (ICLR) at 0.38 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither ICON (ICLR) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither ICON (ICLR) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both ICON (ICLR) at 81.90 and Incyte (INCY) at 61.05 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Incyte (INCY) at 4.06 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Incyte (INCY) at 4.33 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics